Trial Profile
An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory CD30-positive cutaneous T-cell lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Seagen
- 28 Mar 2014 New trial record